02.17.20
Novartis Receives European Approval for Beovu Anti-VEGF Treatment for Wet AMD
Source: Novartis
Novartis announced the European Commission (EC) has approved Beovu (brolucizumab) injection for the treatment of wet age-related macular degeneration (AMD). Beovu is the first EC-approved anti-VEGF treatment to demonstrate superior resolution of retinal fluid (IRF/SRF), a key marker of disease activity, versus aflibercept (secondary endpoints), according to Novartis. Beovu also offers the ability to start eligible wet AMD patients on a 3-month dosing interval immediately after the loading phase. The EC decision is applicable to all 27 European Union member states as well as the UK, Iceland, Norway and Liechtenstein.
“Currently, wet AMD patients, who are often older, can face significant challenges in managing their disease. We believe that Beovu, and its ability to resolve flui
Read Article
Featured Stories
02.11.20
Source: Market Scope
02.10.20
Santen and Verily Establish Joint Venture to Develop and Commercialize Unique Ophthalmic Devices
Source: Santen
02.10.20
Source: Regeneron Pharmaceuticals
Latest News
02.19.20
Palatin Technologies Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial With PL9643Source: Palatin Technologies
02.18.20
Be My Eyes Raises $2.8 Million in Funding for Platform to Support Blind and Visually Impaired WorldwideSource: Be My Eyes
02.18.20
LumiThera to Expand Research into Diabetic Retinopathy for Valeda Light Delivery SystemSource: LumiThera
02.17.20
Alcon Receives FDA Approval for OTC Pataday Once Daily Relief for Allergy ReliefSource: Alcon
02.14.20
Gyroscope Therapeutics Strengthens Senior Leadership Ahead of Next Stage of Company GrowthSource: Gyroscope Therapeutics
02.13.20
Acucela Provides Update on Emixustat Phase 3 Clinical Trial in Patients with Stargardt DiseaseSource: Acucela
02.12.20
Microstent Reduces Post-Cataract Surgery Intraocular Pressure in Glaucoma PatientsSource: Reuters
EPISODE
